Wouter Haazen
Beerse, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.
Journal: Open forum infectious diseases
Published: June 20, 2024
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI.
Journal: NPJ vaccines
Published: October 23, 2023
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Journal: Open forum infectious diseases
Published: April 05, 2023
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
Journal: The Journal of infectious diseases
Published: April 20, 2022
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
Journal: The Journal of infectious diseases
Published: November 12, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic Escherichia coli Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study.
Journal: The Journal of urology
Published: October 20, 2020
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
Journal: The Journal of infectious diseases
Published: February 14, 2020
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.
Journal: The Lancet. Infectious diseases
Published: July 30, 2018
Erratum to "Phase I, randomized, observer-blind, placebo-controlled studies to evaluate the safety, reactogenicity and immunogenicity of an investigational non-typeable Haemophilus influenzae (NTHi) protein vaccine in adults" [Vaccine 34 (2016) 3156-3163].
Journal: Vaccine
Published: September 09, 2017
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Journal: British journal of clinical pharmacology
Published: July 29, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Journal: Clinical pharmacokinetics
Published: June 19, 2016
Last Updated: 09/26/2026